Robust earnings growth, expanding ODM partnerships, margin gains, and a net cash balance sheet position PGEL as a high-quality EMS compounder for FY26 and beyond.
Please provide us the valuation strategy or source that we can do our own valuation
Please provide us the valuation strategy or source that we can do our own valuation